RJA
PGEN icon

Raymond James & Associates’s Precigen PGEN Stock Holding History

Raymond James & Associates’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-174,859
Closed -$248K – 3919
2023
Q3 		$248K Hold
174,859
– – ﹤0.01% 3336
2023
Q2 		$201K Hold
174,859
– – ﹤0.01% 3484
2023
Q1 		$185K Sell
174,859
-633
-0.4% -$913 ﹤0.01% 3512
2022
Q4 		$267K Buy
175,492
+164,658
+1,520% +$283K ﹤0.01% 3286
2022
Q3 		$23K Hold
10,834
– – ﹤0.01% 3787
2022
Q2 		$15K Hold
10,834
– – ﹤0.01% 3901
2022
Q1 		$23K Sell
10,834
-1,375
-11% -$3.35K ﹤0.01% 3985
2021
Q4 		$45K Sell
12,209
-5,850
-32% -$25.2K ﹤0.01% 3960
2021
Q3 		$90K Buy
18,059
+850
+5% +$4.89K ﹤0.01% 3847
2021
Q2 		$112K Buy
17,209
+800
+5% +$5.59K ﹤0.01% 3819
2021
Q1 		$113K Buy
16,409
+828
+5% +$7K ﹤0.01% 3753
2020
Q4 		$159K Buy
+15,581
New +$101K ﹤0.01% 3468
2020
Q3 		– Sell
-20,651
Closed -$103K – 3667
2020
Q2 		$103K Sell
20,651
-17,485
-46% -$59.5K ﹤0.01% 3279
2020
Q1 		$130K Sell
38,136
-1,898
-5% -$8.19K ﹤0.01% 3159
2019
Q4 		$219K Sell
40,034
-1,050
-3% -$5.91K ﹤0.01% 3289
2019
Q3 		$235K Buy
41,084
+380
+0.9% +$2.58K ﹤0.01% 3158
2019
Q2 		$312K Sell
40,704
-3,095
-7% -$16.7K ﹤0.01% 2992
2019
Q1 		$230K Buy
43,799
+15,165
+53% +$105K ﹤0.01% 3151
2018
Q4 		$187K Buy
28,634
+2,834
+11% +$31.8K ﹤0.01% 3160
2018
Q3 		$444K Buy
25,800
+2,419
+10% +$36K ﹤0.01% 2789
2018
Q2 		$326K Sell
23,381
-10,536
-31% -$178K ﹤0.01% 2968
2018
Q1 		$520K Sell
33,917
-905
-3% -$12.9K ﹤0.01% 2548
2017
Q4 		$401K Sell
34,822
-14,307
-29% -$213K ﹤0.01% 2666
2017
Q3 		$934K Buy
49,129
+13,879
+39% +$286K ﹤0.01% 2136
2017
Q2 		$849K Sell
35,250
-1,540
-4% -$33.8K ﹤0.01% 2129
2017
Q1 		$729K Buy
36,790
+1,012
+3% +$22.6K ﹤0.01% 2157
2016
Q4 		$862K Sell
35,778
-9,240
-21% -$257K ﹤0.01% 2005
2016
Q3 		$1.25M Sell
45,018
-7,903
-15% -$209K ﹤0.01% 1743
2016
Q2 		$1.29M Buy
52,921
+2,934
+6% +$83.2K ﹤0.01% 1593
2016
Q1 		$1.68M Buy
49,987
+5,194
+12% +$164K 0.01% 1377
2015
Q4 		$1.34M Buy
44,793
+22,981
+105% +$775K ﹤0.01% 1476
2015
Q3 		$687K Sell
21,812
-4,580
-17% -$223K ﹤0.01% 1786
2015
Q2 		$1.28M Buy
26,392
+2,246
+9% +$94.7K ﹤0.01% 1599
2015
Q1 		$1.05M Buy
24,146
+9,327
+63% +$335K ﹤0.01% 1634
2014
Q4 		$390K Sell
14,819
-2,041
-12% -$44.8K ﹤0.01% 2045
2014
Q3 		$299K Buy
16,860
+471
+3% +$9.62K ﹤0.01% 2038
2014
Q2 		$394K Sell
16,389
-14,774
-47% -$300K ﹤0.01% 1948
2014
Q1 		$783K Buy
+31,163
New +$863K 0.01% 1559

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's PGEN Position: Q4 2023 in Review

Raymond James & Associates sold out of Precigen (PGEN) in Q4 2023, closing a stake of 174,859 shares — an estimated $248K sold.

Raymond James & Associates first reported a position in PGEN in Q1 2014 and held it in 38 quarters. The position peaked at $1.68M in Q1 2016. 137 funds tracked by Wall St. Rank hold PGEN as of Q4 2023.

  • Raymond James & Associates reported no remaining Precigen position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 174,859 Precigen shares in Q4 2023, an estimated $248K.
  • Raymond James & Associates first reported a position in Precigen in Q1 2014 and held it in 38 quarters.
  • Raymond James & Associates's Precigen position peaked at $1.68M in Q1 2016.
  • 137 funds tracked by Wall St. Rank held Precigen as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.